Educational & Research Use Only. Not medical advice. Compounds are research-grade and not FDA-approved unless explicitly noted.
10
Section 10 · 2 compounds

Structural & Cartilage-Specific Regeneration

Cartilage and connective-tissue research, with very limited evidence.

Home/ Sections/ Structural & Cartilage-Specific Regeneration

Cartilage has almost no blood supply, so it heals slowly once damaged. The two entries here are a short Russian bioregulator peptide and a popular commercial blend. Neither has been shown to rebuild cartilage in people.

Each entry opens with an evidence grade, then covers how the compound works, what human, animal and cell studies show, safety, open questions and regulatory status, with numbered references. Grades in this section: D: 1 · E: 1.

E
Evidence grade E · Cell / minimalWhat this means

Published work on the AED peptide is limited to cell cultures, almost all from the developers' network, with no cartilage-specific animal studies or human trials found[1,2,4].

A three-amino-acid synthetic peptide modeled on a cartilage extract, studied only in lab-dish cell experiments; there is no published evidence it repairs joints in animals or people.

Overview

Cartalax is the synthetic tripeptide Ala-Glu-Asp (AED). The developers designed it from a polypeptide complex isolated from animal cartilage, and it belongs to Vladimir Khavinson's family of short "peptide bioregulators"[1,2]. It is a single defined molecule, not a cartilage extract or a mixture. The research comes almost entirely from the St. Petersburg Institute of Bioregulation and Gerontology and its collaborators, much of it in Russian journals[2,4].

Despite being marketed for joints, the published studies do not test cartilage. In aging human skin fibroblasts, AED raised collagen I, SIRT1 and SIRT6[1]. In stem cell cultures, it shifted markers of aging and nerve-cell development[3,4]. A 2023 review by the developers, focused on cartilage, cites no AED data on chondrocytes or classic cartilage genes such as SOX9 or collagen II[2]. No animal joint studies, human trials or 2025 independent replications were found.

A spare key cut from a patternCartalax is like a key cut to match one piece of a larger key ring found in cartilage. It does open some locks in skin and stem cells grown in a dish. Nobody has yet shown that it fits the locks in cartilage, or that it can reach a joint to try them.

Mechanism of Action

Like other Khavinson-group peptides, AED is proposed to act on gene activity rather than a specific receptor. In bone-marrow stem cell aging models, it is reported to modulate aging-related genes including IGF1, FOXO1, TERT, TNKS2 and NFκB, and in kidney cell cultures it is reported to affect the apoptosis marker p53[4]. The developers' 2023 review links these findings to cartilage only by inference: it suggests that effects on IGF1 and the matrix-degrading enzyme MMP9 could matter for osteoarthritis, but it presents no direct chondrocyte data[2].

In aging human skin fibroblasts (passage 14 vs passage 3), baseline SIRT1, SIRT6 and collagen I were 1.8 to 3.6 times lower than in young cells. AED raised collagen I 2.7-fold and SIRT6 11.5-fold in the old cultures, but did not change inflammatory markers such as IL-1 or NF-κB[1]. The cells came from a single donor, and the authors noted that the results differed from their earlier rat-cell work[1]. Whether AED would reach joint tissue after being swallowed or injected has not been studied.

What the Research Shows

Human studies
  • No human clinical trials of Cartalax or the AED peptide have been published in peer-reviewed literature. Marketing references to Russian clinical use in joint and spine conditions could not be traced to a published study.
Animal studies
  • No peer-reviewed animal studies testing AED on cartilage, joints or arthritis models were found. Earlier work in rat skin-cell cultures is cited by the developers but is cell-based, not in living animals[2].
Cell & mechanistic
  • Aging human skin fibroblasts (one donor): AED raised collagen I 2.7-fold, SIRT1 2-fold and SIRT6 11.5-fold in old cultures[1].
  • Human periodontal ligament stem cells (10 donors): AED increased the nerve-development marker GAP43 without reducing proliferation; the strongest effects came from other peptides and the mixture[3].
  • Bone-marrow stem cell and kidney cell aging models: AED is reported to modulate IGF1, FOXO1, TERT, TNKS2, NFκB and p53[4].
What This Could Mean in Practice

Cartalax is at the earliest stage of research. The only published data are lab-dish studies, mostly in skin and stem cells rather than cartilage[1,3,4], and the developers' own cartilage review offers only indirect reasoning[2]. There is no evidence that it rebuilds cartilage, eases joint pain or slows osteoarthritis in animals or people. Claims along those lines are extrapolations, not findings.

Safety & Side Effects
  • No human safety data, adverse-event reports or toxicology studies of AED have been published in peer-reviewed literature.
  • Cell studies showed no reduction in stem cell proliferation, but that is not a safety test[3].
  • Products sold under this name are unregulated, so identity, purity and sterility are not assured.
  • Effects in pregnancy, children, people with cancer, and interactions with medicines are unknown.

Open Questions

  • Whether AED has any effect on chondrocytes or cartilage matrix; this has not been reported[2].
  • Whether it reaches joint tissue after being swallowed or injected.
  • Whether the fibroblast and stem cell findings repeat outside the developers' network; no independent replication was found.
  • Whether long-term changes in growth-related genes such as IGF1 and TERT carry risks[4].

Regulatory Status

Not approved by the FDA, the EMA or another major regulator for any use. It was not among the peptides reviewed at the FDA's July 2026 Pharmacy Compounding Advisory Committee meeting, which considered the related Khavinson-group peptide epitalon[5]. Cartalax is not named individually on the WADA Prohibited List, which separately bars substances not approved for human therapeutic use.

Related Compounds

The Wolverine StackEpitalonGHK-Cu
References (5)
  1. Fridman NV, Linkova NS, Kozhevnikova EO, et al. Comparison of the effects of KE and AED peptides on functional activity of human skin fibroblasts during their replicative aging. Bull Exp Biol Med. 2020. DOI: 10.1007/s10517-020-05022-1
  2. Linkova N, Khavinson V, Diatlova A, et al. Peptide regulation of chondrogenic stem cell differentiation. Int J Mol Sci. 2023;24(9):8415. DOI: 10.3390/ijms24098415
  3. Caputi S, Trubiani O, Sinjari B, et al. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019;33:2058738419828613. DOI: 10.1177/2058738419828613
  4. Khavinson VK, Popovich IG, Linkova NS, et al. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. PMID: 34834147
  5. U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (epitalon evaluation). 2026. fda.gov

Sources last reviewed October 2026.

D
Evidence grade D · Animal onlyWhat this means

The pairing has been tested in one 32-rat tendon study[1]. The only human report involves four patients given BPC-157 with full-length thymosin beta-4, a different molecule from the TB-500 fragment, in an uncontrolled chart review[2].

A popular pairing of two lab-made healing peptides, BPC-157 and TB-500, sold as a 'stack' for tendon and soft-tissue repair, with almost no research on the two used together.

Overview

"The Wolverine Stack" is a marketing name, not a drug. It refers to combining BPC-157, a 15-amino-acid peptide derived from a stomach protein, with TB-500, a synthetic peptide based on thymosin beta-4, a natural protein involved in cell movement and wound repair. Each has its own body of mostly animal research[3,4]. The idea behind the pairing is that two different repair signals might add up to more than either one alone.

That idea has now been tested once, and it did not hold up. In a 2026 rat Achilles tendon study, the combination produced no added benefit over either peptide alone, and TB-500 by itself performed best[1]. Human data on the pair amount to four people in a small knee-pain chart review[2].

Two contractors, one job sitePicture hiring a plumber and an electrician to fix a damaged house at the same time. You might expect the job to go twice as fast, but if both end up waiting on the same drywall crew, adding the second contractor buys you nothing. The one rat study of this pairing looks a lot like that: two workers, no extra speed.

Mechanism of Action

BPC-157 has been studied mainly by one research group in Croatia. In rats with a cut Achilles tendon, it improved load to failure, stiffness and walking function over 14 days, and in cell culture it protected tendon cells from an oxidative toxin, though it did not boost their growth on its own[3]. The proposed mechanisms include new blood vessel formation and effects on growth-factor signaling, but these come almost entirely from animal and cell work.

TB-500 is generally sold as a synthetic thymosin beta-4 or a short fragment of it. Thymosin beta-4 binds actin, the protein scaffold cells use to crawl, and in rats it sped up closure of full-thickness skin wounds[4]. FDA notes it has found no human exposure data for products containing the thymosin beta-4 fragment[5]. In the 2026 tendon study, the authors suggested the two peptides may converge on the same downstream repair pathways, which would explain why combining them added nothing, but they did not test that idea[1].

What the Research Shows

Human studies
  • Retrospective chart review, 2021 (n=16 analyzed, 4 of whom received BPC-157 plus full-length thymosin beta-4, not the TB-500 fragment, follow-up mostly 6 to 12 months): 3 of the 4 combination patients reported less knee pain by phone survey, versus 11 of 12 on BPC-157 alone. There was no control group, outcomes were self-reported, and some figures in the paper are internally inconsistent[2].
  • No randomized or controlled human trial of the pairing has been published.
Animal studies
  • Rats, Achilles tendon cut and repaired (n=32, 8 per group, 4 weeks): only TB-500 significantly raised load to failure versus controls (P<0.05). Tissue scores improved significantly with TB-500 (Bonar P=0.016, Movin P=0.017) and with the combination on Movin only (P=0.040). The combination gave no added benefit over either peptide alone[1].
  • Rats, Achilles tendon transection (BPC-157 alone): higher load to failure, Young's modulus and functional index over 14 days, with smaller tendon defects than saline controls[3].
  • Rats, full-thickness skin wounds (thymosin beta-4 alone): faster re-epithelialization and wound contraction with topical or injected thymosin beta-4[4].
Cell & mechanistic
  • Rat tendon cells: BPC-157 did not change growth on its own but reversed growth inhibition caused by the oxidative toxin 4-hydroxynonenal[3].
What This Could Mean in Practice

Right now there is no evidence that combining BPC-157 and TB-500 works better than either one, and the single controlled study that asked the question found it did not[1]. Even the individual peptides rest mainly on animal research, with human data limited to small, uncontrolled reports[2]. Anyone reading claims of "rapid healing" should understand they come from rat models and from marketing, not from human trials. Whether either peptide helps people recover from tendon injuries is still an open question.

Safety & Side Effects
  • No controlled human safety data exist for the pairing. The 2021 chart review reported no adverse events, but it was not designed to detect them[2].
  • FDA concerns: FDA has stated it has no, or only limited, safety information on BPC-157 for proposed routes, and no human exposure data for the thymosin beta-4 fragment. It also flags immune reactions from peptide aggregation and impurities[5].
  • Product quality: because these products are not approved drugs, identity, purity and sterility are not verified by a regulator[5].
  • Theoretical growth-signal concerns: both peptides are studied for promoting blood vessel growth and cell migration, processes that also matter in tumors. Whether this poses a real risk in people is unknown.

Open Questions

  • Whether the two peptides add to, cancel, or simply duplicate each other in any tissue besides one rat tendon model.
  • Whether the 2026 rat findings at four weeks would hold for longer healing periods or for other injuries such as ligament or muscle tears.
  • What "TB-500" actually contains in a given product (full thymosin beta-4 or a short fragment), which affects how far the animal research applies.
  • Long-term safety of using both peptides together, including immune reactions, in any population.

Regulatory Status

Neither peptide is FDA approved. Both nominations were withdrawn from FDA's Category 2 compounding safety-risk list in April 2026, and in July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend each for the 503A bulks list, against FDA staff advice; FDA has not yet acted[5,7,8]. WADA prohibits BPC-157 under S0 and TB-500 under S2[6].

Related Compounds

BPC-157TB-500
References (8)
  1. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. DOI: 10.52312/jdrs.2026.2951
  2. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435
  3. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. PMID: 14554208
  4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PMID: 10469335
  5. U.S. Food and Drug Administration. Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding (Category 2 and withdrawn nominations). 2026. fda.gov
  6. World Anti-Doping Agency. 2026 Prohibited List (S0 Non-approved substances; S2 Peptide hormones, growth factors, related substances and mimetics). wada-ama.org
  7. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. 2026. fda.gov
  8. McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. July 27, 2026. mcdermottlaw.com

Sources last reviewed October 2026.

← 09 · Longevity & Cellular Aging 11 · Neuroendocrine & Sleep Regulation →